Cambridge Cognition Share Discussion Threads

[igbertsponk] 22/11/2021 12:52

they have to report every movement that moves them a whole percentage (eg from 5.99% to 6.01%), and when they go above or below 3%.

[stockt2] 22/11/2021 12:44

Ah thanks for the help igbertsponk. If it was a sell you would see the before and after % fall on the form yes ? Thanks again.

[igbertsponk] 22/11/2021 12:40

It's a notification they've now got over 3% - either they've bought or just remembered to admit to it!

[stockt2] 22/11/2021 12:32

Is the TR1 today a buy or a sell ?

[daijavu] 22/11/2021 10:14

Smithie6

Which one don't you respect?

[40 fathoms] 21/11/2021 07:01

So what we have suspected for a while now appears to be in the open. Cambridge Cognition and Biogen have a broad development and commercialisation agreement in place with respect to Cognitive testing.



Page 2 footnotes : †This is not a comprehensive list of tools for assessing cognitive function and is not intended to recommend any particular tool.
Eisai and Cogstate have entered into a development and commercialization agreement. Biogen and Cambridge Cognition have entered into a development and commercialization agreement.

I would love to know the full scope and full terms of that agreement. Remember the Eisai/Cogstate agreement is worth a minimum of US$ 45 million over 10 years with upside potential and all development cost borne by Eisai.

So you have to wonder why Cambridge Cognition has not made more of this, confidentiality for sure but I also wonder if they have signed a non exclusive deal. It seems to me that with Cogstate exclusive to Eisai maybe Cambridge see themselves as being the goto partner for the rest of the market. In addition to the various Biogen/Eisai product that could make it to market we could well have competing products from 3 or 4 other pharmas on market in the next 3 or 4 years.

Given this, it seems almost impossible to imagine that it is not Cambridge Cognition providing its technology in to the Biogen/Apple Intuition Study. As a reminder this is a 23,000 participant, iphone and apple watch based multi year observational study of MCI. This is right at the forefront of digital medicine.

[smithie6] 18/11/2021 21:15

arghhh

some financial presentors, I just don't value or respect. Not both of them, just 1 of the 2.

[brummy_git] 10/11/2021 06:31

Professional investor Paul Scott of Stockopedia discussed Cambridge Cognition (starts 48:45) here

[dgwinterbottom] 02/11/2021 07:47

40 fathoms - many thanks, much appreciated!

[40 fathoms] 02/11/2021 07:37

DGW, I think there are probably two factors ... firstly I think the market view that Biogen's Aduhelm (Aducanumab) roll out has not gone well, will have been viewed as a negative by some. My own view is that this would demonstrate a misunderstanding of COGs business model but many associate COG with AD . Secondly, part of the surge in the shareprice was due to a couple of retail trading groups ( you can find details on the internet) and I think they have booked/ are booking their profits and moving on.

[40 fathoms] 02/11/2021 07:27

Never a good look, clearly something has not gone to plan. Reads llike he was let go. A new hire so I am not sure too much can be read in to the situation. Nick Walters is rock solid and knows the business probably better than anyone, I would hope he could be persuaded to take the role full time. If not I am sure Richard Bungay will have some ideas.

[dgwinterbottom] 02/11/2021 07:27

Anyone any thoughts as to why the share price has declined over the last few months?

[purplepelmets] 02/11/2021 07:15

Just a bean counter not exactly the end of the world.

[mobtheplod] 02/11/2021 07:08

CFO done a runner and was not thanked, doesn’t sound too good to me.

[purplepelmets] 26/10/2021 06:13

The great news keeps on rolling. More significant value contract wins.

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")



Cambridge Cognition wins contract for a pivotal schizophrenia clinical trial



Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for a further sizeable schizophrenia trial with an existing customer. Cambridge Cognition has been selected again to provide its proprietary gold standard digital cognitive assessments, CANTABTM, and specialist study management services. The latest contract is worth more than £600,000 to the Company over three years.



Patients with schizophrenia often experience cognitive impairment, with deficits observed in memory, attention and executive function. CANTABTM cognitive assessments can measure these distinct processes with a high degree of sensitivity and so offers a valuable efficacy endpoint for the novel pharmaceutical being investigated.



Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We are delighted with the enduring partnership we have formed with this client and the award of a further order for digital technology solutions from them. This is also great news for us as our strategy is to broaden our offering and expand into more therapeutic areas. Demonstrating the value of digital cognitive assessments in schizophrenia drug development could provide for many more similar opportunities in the future."

[w t tutte] 12/10/2021 23:24

40, I am sure you have seen this ..... it seems like Novartis are pretty happy with Cambridge's ability to predict episodes of unipolar depression. To the extent that they can develop this in to a validated digital biomarker it has the potential to be a huge for them.

The collaborations keep pilling up this year, so far we have Biogen, Novartis and probably Apple. Future is indeed bright. All of this and they have not even begun to unlock the huge potential in the Neurovocalix system.

[40 fathoms] 03/10/2021 00:16

MM84, If you click on the Cambridge Cognition logo on the biogen page it tells you what they are working on. "Self-screening for early diagnosis of MCI, in collaboration with Cambridge Cognition." and it links you to the online test. In the last accounts Cambridge said they landed their first evergreen contract for post marketing of a newly approved drug. It would seem to be a reasonable assumption that it is in fact with Biogen for the Aduhelm rollout.

[mm84] 01/10/2021 12:31

40 Fathoms, what's your view on that link that you've shared of Biogen and Cambridge Cognition?

What do you think they are collaborating on?

Thanks

[40 fathoms] 25/9/2021 11:17

It looks like Monument Therapeutics our @36% owned spinout is not hanging around with the money they have recently raised.

[someuwin] 21/9/2021 14:40

finnCap

"CAMBRIDGE COGNITION (COG): CORP Interims Interim results to 30 June 2021 were in line with the trading update issued on 3 August, which resulted in upgrades to our forecasts and target price. On the back of a 50% (£1.5m) rise in revenues to £4.5m, adjusted EBITDA increased £0.5m to £0.2m, illustrating the operational leverage of 80% gross margin software & services. Period-end cash increased 38% (+£1.2m) in the period to£ 4.2m. Cambridge Cognition is well positioned to be a long-term beneficiary of the trend of running virtual decentralised trials, catalysed by the COVID-pandemic, and evidenced by its first contract that is assessing many thousands of patients at home. We leave forecasts unchanged, and reiterate our target price of 220p, which implies a 2021E EV/sales multiple of 5.6x for its core business and c.15p per share (c.£4.7m) for the value of its interest in Monument Therapeutics."

[someuwin] 21/9/2021 14:15

Bought in here for the first time today.

[40 fathoms] 21/9/2021 11:41

First time I have seen them on Proactive Investors - Good move in my view

[ywdis] 21/9/2021 07:54

Good results also sufficient cash to fund working capital growth.

[40 fathoms] 21/9/2021 07:49

Agreed it is not much, but you would expect a company looking at the growth they are going to achieve in the next 5 years to be significantly loss making. The fact that they are profitable at this point is amazing, 80% gross margins help. Also this was after spending 800k on R&D.

They will be doing a PBT of at least 4 million in FY24 and will still be looking a growth as far as the eye can see.